SIA-31-C18
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 2MG |
|---|---|
| BAC Water | 1ML |
| Amount Per Unit | 0.02MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 250MCG TO 2MG (12 TO 100 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 250 MCG — Titrate Slowly |
Research Overview
SIA-31-C18 (Single Regulator) is a 31-amino acid GLP-1 receptor agonist belonging to the Peptide Receptor Modulator Research Series. It is a semaglutide-class single incretin agonist featuring a C18 fatty diacid (octadecanedioyl) side chain attached via a γ-Glu-2x AEEA linker at Lys20, enabling albumin binding and extended half-life comparable to once-weekly dosing formats. The backbone closely mirrors the GLP-1 incretin sequence with Aib (alpha-aminoisobutyric acid) substitutions at key positions for DPP-4 resistance and enhanced receptor affinity. CAS: 910463-68-2. Structurally analogous in class to semaglutide. Once-weekly subcutaneous injection. Key reference literature: Wilding et al. (NEJM 2021) — once-weekly semaglutide in adults with overweight or obesity, 15% mean weight loss at 68 weeks; Lincoff et al. (NEJM 2023) — semaglutide and cardiovascular outcomes in obesity without diabetes; Perkovic et al. (NEJM 2024) — semaglutide effects on chronic kidney disease.
Commonly Studied With
These peptides are frequently researched alongside Single Regulator (SIA-31-C18): 2mg due to complementary mechanisms:
Single Regulator (SIA-31-C18): 2mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 250MCG TO 2MG (12 TO 100 UNITS)